Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

 

AC IMMUNE SA

 

table of contents

 

FORWARD-LOOKING STATEMENTS 1
PART I 3
ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3
A. Directors and senior management 3
B. Advisers 3
C. Auditors 3
ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3
A. Offer statistics 3
B. Method and expected timetable 3
ITEM 3. KEY INFORMATION 3
A. Selected Financial Data 3
B. Capitalization and indebtedness 4
C. Reasons for the offer and use of proceeds 4
D. Risk factors 4
ITEM 4. INFORMATION ON THE COMPANY 45
A. History and Development of the Company 45
B. Business overview 45
C. Organizational structure 95
D. Property, plant and equipment 96
ITEM 4A. UNRESOLVED STAFF COMMENTS 96
ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 96
A. Operating results 96
C. Research and development, patents and licenses, etc. 114
D. Trend information 115
E. Off-balance sheet arrangements 115
F. Tabular disclosure of contractual obligations 115
G. Safe harbor 115
H. Non-IFRS Financial Measures 115
ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 116
A. Directors and senior management 116
B. Compensation 119
C. Board practices 121
D. Employees 123
E. Share ownership 123
ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 123
A. Major shareholders 123
B. Related party transactions 126
C. Interests of Experts and Counsel 127
ITEM 8. FINANCIAL INFORMATION 127
A. Consolidated statements and other financial information 127
B. Significant changes 128
ITEM 9. THE OFFER AND LISTING 128
A. Offering and listing details 128
B. Plan of distribution 128
C. Selling shareholders 128
D. Dilution 128
E. Expenses of the issue 128
ITEM 10. ADDITIONAL INFORMATION 128
A. Share capital 128
B. Memorandum and articles of association 128
C. Material contracts 128
D. Exchange controls 129
E. Taxation 129
F. Dividends and paying agents 134
G. Statement by experts 134
H. Documents on display 134
I. Subsidiary information 134
ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 135
ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 136
A. Debt securities 136
B. Warrants and rights 136
C. Other securities 136
D. American Depositary Shares 136
PART II   136
ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES 136
A. Defaults 136
B. Arrears and delinquencies 136
ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS 136
E. Use of Proceeds 136
ITEM 15. CONTROLS AND PROCEDURES 137
A. Disclosure Controls and Procedures 137
B. Management’s Annual Report on Internal Control over Financial Reporting 137
C. Attestation Report of the Registered Public Accounting Firm 137
D. Changes in Internal Control over Financial Reporting 137
ITEM 16. [RESERVED] 137
ITEM 16A. Audit committee financial experts 137
ITEM 16B. Code of ethics 137
ITEM 16C. Principal accountant fees and services (in CHF and thousands) 137
ITEM 16D. Exemptions from the listing standards for audit committees 138
ITEM 16E. Purchases of equity securities by the issuer and affiliated purchasers 138
ITEM 16F. Change in registrant’s certifying accountant 138
ITEM 16G. Corporate governance 138
ITEM 16H. Mine safety disclosure 139
PART III 139
ITEM 17. Financial statements 139
ITEM 18. Financial statements 139
ITEM 19. Exhibits 140

 

i 


© AC Immune 2015